A Phase-II/III, Partially Double-blind, Randomized, Active-controlled, Multicentric Study to Assess the immunogenicity and Safety of SIIPL’s qHPV Vaccine Administered Intramuscularly in Healthy Volunteers according to a Two-dose Schedule to Cohort 1 (Girls and Boys Aged 9-14 years) and a Three-dose Schedule to Cohort 2 (Women and Men Aged 15-26 years) as Compared to Merck’s HPV6/11/16/18 vaccine (Gardasil®).

Serum Institute of India Pvt Ltd0 个研究点目标入组 2,307 人开始时间: 待定最近更新: 2024年5月27日

试验速览

阶段: 2 期
状态: 已完成
发起方: Serum Institute of India Pvt Ltd
入组人数: 2,307

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1) Healthy ambulant male and female subjects aged 9-26 years.
•2) Females with intact uterus and not pregnant.
•Subject who are married/sexually active must agree to use effective contraception through Month 7 of the study.
•3) Subjects who have not yet had sexual intercourse must either agree to remain abstinent through the 7 month study period, or if they become sexually active during the vaccination phase of the study, to use effective contraception for the 7 month study period.
•4) Subject’s willingness and ability to comply with the requirements of the protocol as judged by the investigator.
•5) Subject willing to sign a written informed consent (for subjects 18 years and above).
•6) Either of the parent is willing to sign written informed consent form and subject is willing to sign written assent form (for subject <18 years of age).
•7) Married females must agree to refrain from sexual activity for 48 hours prior to any
•scheduled visit that includes a cervical sample.

排除标准

•1)Subject has a known history of prior vaccination with HPV vaccine.
•2)Subject concurrently enrolled in clinical studies of investigational agents or studies involving collection of cervical/genital specimens.
•3) Subject with a current diagnosis or prior history of genital warts or treatment of genital warts.
•4)Female subject with current diagnosis or history of treatment for cervical pre-malignancies or malignancy.
•5)Female subject attempting to be pregnant for the study period 7 month.
•6)Married female subject has clinical evidence of gross purulent cervicitis
•7)Male subject with a current diagnosis or prior history of penile or anal cancers.
•8)Subject has a history of any allergic diseases or severe allergic reaction to any agent
•9)Subject has had an acute illness and/or fever at the time of vaccination or during the 7 days prior to the vaccination.
•10)Subject is currently immunocompromised or has been diagnosed as having a congenital or acquired Human Immunodeficiency Virus infection.
•11) coagulation disorder that would contraindicate IM injections.
•12)Subject has history of any major pulmonary, cardiovascular, renal, neurological, metabolic, gastro-intestinal, hepato-biliary, haematological functional abnormality, mental or physical disability, blood dyscrasia or any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives.
•13)Subject has history of any cancer, organ transplant or any other immune system disease.
•14)Subject has had chronic administration of high doses of corticosteroids, cytotoxic agents or radiotherapy or immunoglobulins, immunosuppressants or other immune-modifying drugs in last 3 months or planned at any time during the study.
•15)Subject has received any oral or injectable antibiotics and/or antiviral from five days before screening through to enrolment.
•16)Subject has history of receiving a blood transfusion or other blood products in three months prior to screening.
•17)Subject has history of administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned during the course of 7 month study period.

研究者

发起方

Serum Institute of India Pvt Ltd

相似试验

进行中（未招募）

不适用

Etoricoxib and placebo in patients with rheumatoid arthritisRheumatoid Arthritis (RA)MedDRA version: 15.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders

EUCTR2010-019871-31-ATMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,800

进行中（未招募）

不适用

Etoricoxib and placebo in patients with rheumatoid arthritisRheumatoid Arthritis (RA)MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders

EUCTR2010-019871-31-FIMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,800

已完成

3 期

A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA)

CTRI/2011/07/001926Merck Sharp and Dohme1,776

进行中（未招募）

不适用

Etoricoxib and placebo in patients with rheumatoid arthritisRheumatoid Arthritis (RA)MedDRA version: 17.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders

EUCTR2010-019871-31-LTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,250

进行中（未招募）

不适用

EUCTR2010-019871-31-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,250